The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies
Open accessAbstract
New treatments for multiple sclerosis (MS) focused on B cells have created an atmosphere of excitement in the MS community. B cells are now known to play a major role in disease, demonstrated by the highly impactful effect of a B cell-depleting antibody on controlling MS. The idea that a virus may play a role in the development of MS has a long history and is supported mostly by studies demonstrating a link between B cell-tropic Epstein-Barr virus (EBV) and disease onset. Efforts to develop antiviral strategies for treating MS are underway. Although gaps remain in our understanding of the etiology of MS, the role, if any, of viruses in propagating pathogenic immune responses deserves attention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1601277 · Cited by 2,021
Self-citationWucherpfennig, K. W., & Strominger, J. L. (1995) · Cell · doi:10.1016/0092-8674(95)90348-8 · Cited by 1,534
Serafini, B., Rosicarelli, B., Magliozzi, R., Stigliano, E., & Aloisi, F. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00049.x · Cited by 1,208
Persistence of the Epstein–Barr Virus and the Origins of Associated Lymphomas
Thorley-Lawson, D. A., & Gross, A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032015 · Cited by 1,054
Environmental risk factors for multiple sclerosis. Part I: The role of infection
Ascherio, A., & Munger, K. L. (2007) · Annals of Neurology · doi:10.1002/ana.21117 · Cited by 1,042
Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain
Serafini, B., Rosicarelli, B., Franciotta, D., Magliozzi, R., Reynolds, R., Cinque, P., Andreoni, L., Trivedi, P., Salvetti, M., Faggioni, A., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20071030 · Cited by 766
Epstein-Barr Virus Antibodies and Risk of Multiple Sclerosis: A Prospective Study
Ascherio, A., Munger, K. L., Lennette, E. T., Spiegelman, D., Hernán, M. A., Olek, M. J., Hankinson, S. E., & Hunter, D. J. (2001) · JAMA · doi:10.1001/jama.286.24.3083 · Cited by 549
Multiple sclerosis: experimental models and reality
Lassmann, H., & Bradl, M. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1631-4 · Cited by 525
Efficacy Results of a Trial of a Herpes Simplex Vaccine
Belshe, R. B., Leone, P. A., Bernstein, D. I., Wald, A., Levin, M. J., Stapleton, J. T., Gorfinkel, I., Morrow, R. L. A., Ewell, M. G., Stokes-Riner, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1103151 · Cited by 510
Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis
Jelcic, I., Al Nimer, F., Wang, J., Lentsch, V., Planas, R., Jelcic, I., Madjovski, A., Ruhrmann, S., Faigle, W., Frauenknecht, K., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.011 · Cited by 508
B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes
Stern, J. N. H., Yaari, G., Vander Heiden, J. A., Church, G., Donahue, W. F., Hintzen, R. Q., Huttner, A. J., Laman, J. D., Nagra, R. M., Nylander, A., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008879 · Cited by 441
Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity
Harley, J. B., Chen, X., Pujato, M., Miller, D., Maddox, A., Forney, C., Magnusen, A. F., Lynch, A., Chetal, K., Yukawa, M., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0102-3 · Cited by 406
Reassessing B cell contributions in multiple sclerosis
Li, R., Patterson, K. R., & Bar-Or, A. (2018) · Nature Immunology · doi:10.1038/s41590-018-0135-x · Cited by 401
Self-citationBanwell, B., Krupp, L., Kennedy, J., Tellier, R., Tenembaum, S., Ness, J., Belman, A., Boiko, A., Bykova, O., Waubant, E., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70196-5 · Cited by 344
Self-citationLünemann, J. D., Jelčić, I., Roberts, S., Lutterotti, A., Tackenberg, B., Martin, R., & Münz, C. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072397 · Cited by 334
The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis
Kieseier, B. C. (2011) · CNS Drugs · doi:10.2165/11591110-000000000-00000 · Cited by 308
Multiple Sclerosis Is an Inflammatory T-Cell–Mediated Autoimmune Disease
Weiner, H. L. (2004) · Archives of Neurology · doi:10.1001/archneur.61.10.1613 · Cited by 293
Human Endogenous Retroviruses in Neurological Diseases
Küry, P., Nath, A., Créange, A., Dolei, A., Marche, P., Gold, J., Giovannoni, G., Hartung, H.-P., & Perron, H. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.02.007 · Cited by 288
Self-citationInfection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases
Pender, M. P. (2003) · Trends in Immunology · doi:10.1016/j.it.2003.09.005 · Cited by 285
Self-citationEpstein–Barr Virus Infection and Multiple Sclerosis: A Review
Ascherio, A., & Munger, K. L. (2010) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-010-9201-3 · Cited by 259
B cell exchange across the blood-brain barrier in multiple sclerosis
von Büdingen, H.-C., Kuo, T. C., Sirota, M., van Belle, C. J., Apeltsin, L., Glanville, J., Cree, B. A., Gourraud, P.-A., Schwartzburg, A., Huerta, G., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63842 · Cited by 239
The Genetics of Multiple Sclerosis: From 0 to 200 in 50 Years
Baranzini, S. E., & Oksenberg, J. R. (2017) · Trends in Genetics · doi:10.1016/j.tig.2017.09.004 · Cited by 239
Lünemann, J. D., Tintoré, M., Messmer, B., Strowig, T., Rovira, Á., Perkal, H., Caballero, E., Münz, C., Montalban, X., & Comabella, M. (2010) · Annals of Neurology · doi:10.1002/ana.21886 · Cited by 229
High seroprevalence of Epstein–Barr virus in children with multiple sclerosis
Pohl, D., Krone, B., Rostasy, K., Kahler, E., Brunner, E., Lehnert, M., Wagner, H. J., Gärtner, J., & Hanefeld, F. (2006) · Neurology · doi:10.1212/01.wnl.0000247665.94088.8d · Cited by 226
IL-10, T cell exhaustion and viral persistence
Blackburn, S. D., & Wherry, E. J. (2007) · Trends in Microbiology · doi:10.1016/j.tim.2007.02.006 · Cited by 219
Environmental Risk Factors for Multiple Sclerosis: A Review with a Focus on Molecular Mechanisms
O’Gorman, C., Lucas, R., & Taylor, B. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms130911718 · Cited by 209
Lassmann, H., Niedobitek, G., Aloisi, F., Middeldorp, J. M., & the NeuroproMiSe EBV Working Group (2011) · Brain · doi:10.1093/brain/awr197 · Cited by 190
Pender, M. P. (2012) · Autoimmune Diseases · doi:10.1155/2012/189096 · Cited by 189
Self-citationJochum, S., Moosmann, A., Lang, S., Hammerschmidt, W., & Zeidler, R. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002704 · Cited by 188
The Essential Role of Epstein-Barr Virus in the Pathogenesis of Multiple Sclerosis
Pender, M. P. (2010) · The Neuroscientist · doi:10.1177/1073858410381531 · Cited by 186
Self-citationImmune Evasion by Epstein-Barr Virus
Ressing, M. E., van Gent, M., Gram, A. M., Hooykaas, M. J. G., Piersma, S. J., & Wiertz, E. J. H. J. (2015) · Current topics in microbiology and immunology · doi:10.1007/978-3-319-22834-1_12 · Cited by 182
Multiple sclerosis: Prospects and promise
Hauser, S. L., Chan, J. R., & Oksenberg, J. R. (2013) · Annals of Neurology · doi:10.1002/ana.24009 · Cited by 179
Mameli, G., Poddighe, L., Mei, A., Uleri, E., Sotgiu, S., Serra, C., Manetti, R., & Dolei, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044991 · Cited by 179
Angelini, D. F., Serafini, B., Piras, E., Severa, M., Coccia, E. M., Rosicarelli, B., Ruggieri, S., Gasperini, C., Buttari, F., Centonze, D., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003220 · Cited by 174
Michel, L., Touil, H., Pikor, N. B., Gommerman, J. L., Prat, A., & Bar-Or, A. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00636 · Cited by 173
Self-citationCommon viruses associated with lower pediatric multiple sclerosis risk
Waubant, E., Mowry, E. M., Krupp, L., Chitnis, T., Yeh, E. A., Kuntz, N., Ness, J., Chabas, D., Strober, J., McDonald, J., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821e552a · Cited by 171
Cell-based therapeutic strategies for multiple sclerosis
Scolding, N. J., Pasquini, M., Reingold, S. C., Cohen, J. A., Sclerosis:, I. C. O. C.-B. T. F. M., Atkins, H., Banwell, B., Bar-Or, A., Bebo, B., Bowen, J., et al. (2017) · Brain · doi:10.1093/brain/awx154 · Cited by 170
Self-citationInterferon β for Multiple Sclerosis
Jakimovski, D., Kolb, C., Ramanathan, M., Zivadinov, R., & Weinstock-Guttman, B. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a032003 · Cited by 170
Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis
Jilek, S., Schluep, M., Meylan, P., Vingerhoets, F., Guignard, L., Monney, A., Kleeberg, J., Le Goff, G., Pantaleo, G., & Du Pasquier, R. A. (2008) · Brain · doi:10.1093/brain/awn108 · Cited by 169
Zivadinov, R., Guan, Y., Jakimovski, D., Ramanathan, M. K., & Weinstock‐Guttman, B. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.245462 · Cited by 167
Hassani, A., Corboy, J. R., Al-Salam, S., & Khan, G. (2018) · PLOS ONE · doi:10.1371/journal.pone.0192109 · Cited by 163
Epstein-Barr virus–specific T cell therapy for progressive multiple sclerosis
Pender, M. P., Csurhes, P. A., Smith, C., Douglas, N. L., Neller, M. A., Matthews, K. K., Beagley, L., Rehan, S., Crooks, P., Hopkins, T. J., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.124714 · Cited by 159
Self-citationPeferoen, L. A. N., Lamers, F., Lodder, L. N. R., Gerritsen, W. H., Huitinga, I., Melief, J., Giovannoni, G., Meier, U., Hintzen, R. Q., Verjans, G. M. G. M., et al. (2010) · Brain · doi:10.1093/brain/awp296 · Cited by 158
Self-citationOcrelizumab: a new milestone in multiple sclerosis therapy
Mulero, P., Midaglia, L. S., & Montalbán, X. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286418773025 · Cited by 153
Association of innate immune activation with latent Epstein-Barr virus in active MS lesions
Tzartos, J. S., Khan, G., Vossenkämper, A., Sádaba, M. C., Lonardi, S., Sefia, E., Meager, A., Elia, A., Middeldorp, J. M., Clemens, M. J., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31823ed057 · Cited by 151
Self-citationMagliozzi, R., Serafini, B., Rosicarelli, B., Chiappetta, G., Veroni, C., Reynolds, R., & Aloisi, F. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31827bfc62 · Cited by 150
Defective T‐cell control of Epstein–Barr virus infection in multiple sclerosis
Pender, M. P., Csurhes, P. A., Burrows, J. M., & Burrows, S. R. (2017) · Clinical & Translational Immunology · doi:10.1038/cti.2016.87 · Cited by 145
Self-citationVaccine Development for Epstein-Barr Virus
Cohen, J. I. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-7230-7_22 · Cited by 142
Immune Therapy for Autoimmune Diseases
Steinman, L. (2004) · Science · doi:10.1126/science.1099896 · Cited by 141
Self-citationEpstein–Barr virus and multiple sclerosis: potential opportunities for immunotherapy
Pender, M. P., & Burrows, S. R. (2014) · Clinical & Translational Immunology · doi:10.1038/cti.2014.25 · Cited by 141
Self-citationMolecular signature of Epstein-Barr virus infection in MS brain lesions
Moreno, M. A., Or‐Geva, N., Aftab, B. T., Khanna, R., Croze, E., Steinman, L., & Han, M. H. (2018) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000466 · Cited by 138
Self-citationPathogenesis of Murine Coronavirus in the Central Nervous System
Bender, S. J., & Weiss, S. R. (2010) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-010-9202-2 · Cited by 132
Cytokine-Defined B Cell Responses as Therapeutic Targets in Multiple Sclerosis
Li, R., Rezk, A., Healy, L. M., Muirhead, G., Prat, A., Gommerman, J. L., & Bar‐Or, A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00626 · Cited by 124
Self-citationPersistence of Epstein-Barr Virus in Self-Reactive Memory B Cells
Tracy, S. I., Kakalacheva, K., Lünemann, J. D., Luzuriaga, K., Middeldorp, J. M., & Thorley‐Lawson, D. A. (2012) · Journal of Virology · doi:10.1128/jvi.01699-12 · Cited by 107
Pender, M. P., Csurhes, P. A., Lenarczyk, A., Pfluger, C. M., & Burrows, S. R. (2008) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.161018 · Cited by 106
Self-citationMolecular Mimicry in Multiple Sclerosis
Libbey, J. E., McCoy, L. L., & Fujinami, R. S. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(07)79006-2 · Cited by 102
van Noort, J. M., Bajramovic, J. J., Plomp, A. C., & van Stipdonk, M. J. B. (2000) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(00)00181-8 · Cited by 97
Wanke, F., Moos, S., Croxford, A. L., Heinen, A. P., Gräf, S., Kalt, B., Tischner, D., Zhang, J., Christen, I., Bruttger, J., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.01.020 · Cited by 97
Veroni, C., Serafini, B., Rosicarelli, B., Fagnani, C., & Aloisi, F. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-017-1049-5 · Cited by 90
Rizzo, F., Giacomini, E., Mechelli, R., Buscarinu, M. C., Salvetti, M., Severa, M., & Coccia, E. M. (2016) · Immunology and Cell Biology · doi:10.1038/icb.2016.55 · Cited by 87
Viruses and cells intertwined since the dawn of evolution
Durzyńska, J., & Goździcka‐Józefiak, A. (2015) · Virology Journal · doi:10.1186/s12985-015-0400-7 · Cited by 85
EBV-Related Lymphomas: New Approaches to Treatment
Kanakry, J. A., & Ambinder, R. F. (2013) · Current Treatment Options in Oncology · doi:10.1007/s11864-013-0231-y · Cited by 84
Sutton, M. Y., Jones, R. L., Wolitski, R. J., Cleveland, J. C., Dean, H. D., & Fenton, K. A. (2009) · American Journal of Public Health · doi:10.2105/ajph.2008.157958 · Cited by 82
Loss of RASGRP1 in humans impairs T‐cell expansion leading to Epstein‐Barr virus susceptibility
Winter, S., Martin, E., Boutboul, D., Lenoir, C., Boudjemaa, S., Petit, A., Pïcard, C., Fischer, A., Leverger, G., & Latour, S. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201708292 · Cited by 82
The discovery of natalizumab, a potent therapeutic for multiple sclerosis
Steinman, L. (2012) · The Journal of Cell Biology · doi:10.1083/jcb.201207175 · Cited by 76
Self-citationOgembo, J. G., Muraswki, M. R., McGinnes, L. W., Parcharidou, A., Sutiwisesak, R., Tison, T., Avendano, J., Agnani, D., Finberg, R. W., Morrison, T. G., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0415-2 · Cited by 76
Epstein–Barr virus and multiple sclerosis. From evidence to therapeutic strategies
Menéndez, S. F., Fernández-Morán, M., Fernández‐Vega, I., Pérez-Álvarez, Á. I., & Villafani, J. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.01.013 · Cited by 76
Ocrelizumab: A Review in Multiple Sclerosis
Syed, Y. Y. (2018) · CNS Drugs · doi:10.1007/s40263-018-0568-7 · Cited by 76
Multiple Sclerosis: Perspectives in Treatment and Pathogenesis
Palumbo, S., & PELLEGRINI, S. (2017) · Codon Publications eBooks · doi:10.15586/codon.multiplesclerosis.2017 · Cited by 74
Casiraghi, C., Shanina, I., Cho, S., Freeman, M. L., Blackman, M. A., & Horwitz, M. S. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002715 · Cited by 72
Bittner, S., Ruck, T., Wiendl, H., Grauer, O. M., & Meuth, S. G. (2016) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285616666741 · Cited by 72
Improving DNA Vaccine Performance Through Vector Design
Williams, J. (2014) · Current Gene Therapy · doi:10.2174/156652321403140819122538 · Cited by 68
Multiple sclerosis: an example of pathogenic viral interaction?
Fierz, W. (2017) · Virology Journal · doi:10.1186/s12985-017-0719-3 · Cited by 67
Morandi, E., Jagessar, S. A., Hart, B. A. ‘., & Gran, B. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700178 · Cited by 66
The primate autoimmune encephalomyelitis model; a bridge between mouse and man
Hart, B. A. ‘., van Kooyk, Y., Geurts, J. J. G., & Gran, B. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.194 · Cited by 65
Epstein-Barr virus genetic variants are associated with multiple sclerosis
Mechelli, R., Manzari, C., Policano, C., Annese, A., Picardi, E., Umeton, R., Fornasiero, A., D’Erchia, A. M., Buscarinu, M. C., Agliardi, C., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001420 · Cited by 63
Afrasiabi, A., Parnell, G. P., Fewings, N., Schibeci, S. D., Basuki, M. A., Chandramohan, R., Zhou, Y., Taylor, B. V., Brown, D. A., Swaminathan, S., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0640-z · Cited by 62
Cencioni, M. T., Magliozzi, R., Nicholas, R. S., Ali, R., Malik, O., Reynolds, R., Borsellino, G., Battistini, L., & Muraro, P. A. (2017) · Immunology · doi:10.1111/imm.12808 · Cited by 60
D’Addario, M., Libermann, T. A., Xu, J., Ahmad, A., & Menézes, J. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4589 · Cited by 57
Gieß, R. M., Pfuhl, C., Behrens, J. R., Rasche, L., Freitag, E., Khalighy, N., Otto, C., Wuerfel, J. T., Brandt, A. U., Hofmann, J., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175279 · Cited by 55
The promise of a prophylactic Epstein–Barr virus vaccine
Balfour, H. H., Schmeling, D. O., & Geris, J. M. (2019) · Pediatric Research · doi:10.1038/s41390-019-0591-5 · Cited by 55
Epstein-Barr–negative MS: a true phenomenon?
Dobson, R., Kühle, J., Middeldorp, J. M., & Giovannoni, G. (2017) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000318 · Cited by 54
Self-citationIL-10: Achieving Balance During Persistent Viral Infection
Ng, C. T., & Oldstone, M. B. A. (2014) · Current topics in microbiology and immunology · doi:10.1007/978-3-662-43492-5_6 · Cited by 52
Oxysterol‐EBI2 signaling in immune regulation and viral infection
Daugvilaite, V., Arfelt, K. N., Benned‐Jensen, T., Sailer, A. W., & ROSENKILDE, M. M. (2014) · European Journal of Immunology · doi:10.1002/eji.201444493 · Cited by 50
Peacock, J. W., Elsawa, S. F., Petty, C. C., Hickey, W. F., & Bost, K. L. (2003) · European Journal of Immunology · doi:10.1002/eji.200323148 · Cited by 50
Clottu, A., Mathias, A., Sailer, A. W., Schluep, M., Seebach, J. D., Pasquier, R. D., & Pot, C. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.006 · Cited by 50
EBV Infection and Multiple Sclerosis: Lessons from a Marmoset Model
Hart, B. A. ‘., Kap, Y. S., Morandi, E., Laman, J. D., & Gran, B. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.10.007 · Cited by 45
Protective and Detrimental Roles for Regulatory T Cells in a Viral Model for Multiple Sclerosis
Martinez, N. E., Karlsson, F. J., Sato, F., Kawai, E., Omura, S., Minagar, A., Grisham, M. B., & Tsunoda, I. (2014) · Brain Pathology · doi:10.1111/bpa.12119 · Cited by 44
Nociti, V., Frisullo, G., Marti, A., Luigetti, M., Iorio, R., Patanella, A. K., Bianco, A. D., Tonali, P., Grillo, R., Sabatelli, M., et al. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.04.007 · Cited by 42
Time correlation between mononucleosis and initial symptoms of MS
Endriz, J. G., Ho, P. P.-K., & Steinman, L. (2017) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000308 · Cited by 39
Self-citationOpsahl, M. L., & Kennedy, P. G. E. (2007) · Journal of Neurology · doi:10.1007/s00415-006-0316-7 · Cited by 37
Experimental In Vivo Models of Multiple Sclerosis: State of the Art
Palumbo, S., & Pellegrini, S. (2017) · Codon Publications eBooks · doi:10.15586/codon.multiplesclerosis.2017.ch11 · Cited by 36
EBI2 regulates pro-inflammatory signalling and cytokine release in astrocytes
Rutkowska, A., Shimshek, D. R., Sailer, A. W., & Dev, K. K. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.029 · Cited by 36
The Role of Latently Infected B Cells in CNS Autoimmunity
Márquez, A. C., & Horwitz, M. S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00544 · Cited by 33
Gold, J., Marta, M., Meier, U., Christensen, T., Miller, D. H., Altmann, D. R., Holden, D., Bianchi, L., Adiutori, R., MacManus, D. G., et al. (2018) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2018.06.002 · Cited by 33
Self-citationEpstein–Barr virus nuclear antigen-1 B-cell epitopes in multiple sclerosis twins
Mechelli, R., Anderson, J., Vittori, D., Coarelli, G., Annibali, V., Cannoni, S., Aloisi, F., Salvetti, M., Ja, J., & Ristori, G. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458511410515 · Cited by 31
Heterogeneity in association of remote herpesvirus infections and pediatric MS
Nourbakhsh, B., Rutatangwa, A., Waltz, M., et al. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.636 · Cited by 31
Infectious mononucleosis and multiple sclerosis – Updated review on associated risk
Sheik‐Ali, S. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.02.019 · Cited by 30
EBV-specific immune responses in patients with multiple sclerosis responding to IFNβ therapy
Comabella, M., Kakalacheva, K., Río, J., Münz, C., Montalbán, X., & Lünemann, J. D. (2011) · Multiple Sclerosis Journal · doi:10.1177/1352458511426816 · Cited by 29
Evaluation of Epstein-Barr virus-specific antibodies in Cypriot multiple sclerosis patients
Deeba, E., Koptides, D., Gaglia, E., Constantinou, A., Lambrianides, A., Pantzaris, M., Krashias, G., & Christodoulou, C. (2018) · Molecular Immunology · doi:10.1016/j.molimm.2018.12.010 · Cited by 29
Zivadinov, R., Ramanathan, M. K., Hagemeier, J., Bergsland, N., Ramasamy, D. P., Durfee, J., Kolb, C., & Weinstock‐Guttman, B. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2019.101388 · Cited by 29
The Development of Prophylactic and Therapeutic EBV Vaccines
Smith, C., & Khanna, R. (2015) · Current topics in microbiology and immunology · doi:10.1007/978-3-319-22834-1_16 · Cited by 28
Self-citationTrials of antivirals in the treatment of multiple sclerosis
Lycke, J. (2017) · Acta Neurologica Scandinavica · doi:10.1111/ane.12839 · Cited by 28
The effect of B-cell depletion in the Theiler's model of multiple sclerosis
Gilli, F., Li, L., Campbell, S. J., Anthony, D. C., & Pachner, A. R. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2015.10.012 · Cited by 23
A genetic basis for multiple sclerosis severity: Red herring or real?
Jokubaitis, V., & Butzkueven, H. (2016) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2016.08.007 · Cited by 22
Virally-Induced Upregulation of Heparan Sulfate on B Cells via the Action of Type I IFN
Jarousse, N., Trujillo, D. L., Wilcox‐Adelman, S. A., & Coscoy, L. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003495 · Cited by 21
EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas
McLaughlin, L. P., Gottschalk, S. M., Rooney, C. M., & Bollard, C. M. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6655-4_19 · Cited by 20
Analysis of the cross‐talk of Epstein–Barr virus‐infected B cells with T cells in the marmoset
Dunham, J., van Driel, N., Eggen, B. J. L., Paul, C., Hart, B. A. ‘., Laman, J. D., & Kap, Y. S. (2017) · Clinical & Translational Immunology · doi:10.1038/cti.2017.1 · Cited by 20
Croze, E. (2010) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2010.0022 · Cited by 19
Self-citationRole of Immunological Memory Cells as a Therapeutic Target in Multiple Sclerosis
Bose, T. (2017) · Brain Sciences · doi:10.3390/brainsci7110148 · Cited by 19
Ikram, M. A., Vernooij, M. W., Roshchupkin, G. V., Albert Hofman, D., van Duijn, C. M., Uitterlinden, A. G., Niessen, W. J., Hintzen, R. Q., & Adams, H. H. H. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516682104 · Cited by 15
Cited by
Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM
Lanz, T. V., Brewer, R. C., Ho, P. P., Moon, J.-S., Jude, K. M., Fernandez, D., Fernandes, R. A., Gomez, A. M., Nadj, G.-S., Bartley, C. M., et al. (2022) · Nature · doi:10.1038/s41586-022-04432-7 · Cited by 908
Self-citationEpstein-Barr Virus and Systemic Autoimmune Diseases
Houen, G., & Trier, N. H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.587380 · Cited by 379
B and T Cells Driving Multiple Sclerosis: Identity, Mechanisms and Potential Triggers
van Langelaar, J., Rijvers, L., Smolders, J., & van Luijn, M. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00760 · Cited by 319
Epstein-Barr virus and multiple sclerosis
Robinson, W. H., & Steinman, L. (2022) · Science · doi:10.1126/science.abm7930 · Cited by 310
Self-citationGene–environment interactions and their impact on human health
Virolainen, S. J., VonHandorf, A., Viel, K. C. M. F., Weirauch, M. T., & Kottyan, L. C. (2022) · Genes & Immunity · doi:10.1038/s41435-022-00192-6 · Cited by 301
Metadata
- Authors
- Bar-Or, A., Pender, M. P., Khanna, R., Steinman, L., Hartung, H.-P., Maniar, T., Croze, E., Aftab, B. T., Giovannoni, G., & Joshi, M. A.
- Venue
- Trends in Molecular Medicine
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 26
- Issue
- 3
- Pages
- 296-310
- ISSN
- 1471-4914 (ISSN-L)
- OpenAlex
- W2994779767
- Cited by
- 262
- References
- 111
- FWCI
- 6.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.